Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Meraviglia-Crivelli

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Biomedicines|April 3, 2021
Oligonucleotide-Based Therapies for Renal DiseasesFernando Cartón-García, Cassondra Jeanette Saande, Daniel Meraviglia-Crivelli, et al.
Pharmaceuticals (Basel, Switzerland)|October 21, 2018
Aptamer-iRNAs as Therapeutics for Cancer TreatmentMario M Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P Menon, et al.
Iscience|February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapyMartin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Molecular Therapy. Nucleic Acids|August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progressionDaniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids|June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
Cancer Immunology, Immunotherapy : CII|March 25, 2018
Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signalsJavier Arranz-Nicolás, Jesús Ogando, Denise Soutar, et al.
Cancers|February 25, 2023
Modulating T Cell Responses by Targeting CD3Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Oncoimmunology|September 18, 2018
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumorsMario M Soldevilla, Helena Villanueva, Naiara Martinez-Velez, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2019
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor ImmunityMario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biomedicines|August 26, 2022
Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune SystemDaniel Meraviglia-Crivelli, Angelina Zheleva, Martin Barainka, et al.
Biomedicines|April 3, 2021
Oligonucleotide-Based Therapies for Renal DiseasesFernando Cartón-García, Cassondra Jeanette Saande, Daniel Meraviglia-Crivelli, et al.
Pharmaceuticals (Basel, Switzerland)|October 21, 2018
Aptamer-iRNAs as Therapeutics for Cancer TreatmentMario M Soldevilla, Daniel Meraviglia-Crivelli de Caso, Ashwathi P Menon, et al.
Iscience|February 2, 2026
Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapyMartin Barainka, Angelina Zheleva, Angela Pérez-Cervera, et al.
Molecular Therapy. Nucleic Acids|August 22, 2022
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progressionDaniel Meraviglia-Crivelli, Helena Villanueva, Ashwathi Puravankara Menon, et al.
Molecular Therapy. Nucleic Acids|June 26, 2020
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Mayte Sola, Ashwathi Puravankara Menon, Beatriz Moreno, et al.
Cancer Immunology, Immunotherapy : CII|March 25, 2018
Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signalsJavier Arranz-Nicolás, Jesús Ogando, Denise Soutar, et al.
Cancers|February 25, 2023
Modulating T Cell Responses by Targeting CD3Ashwathi Puravankara Menon, Beatriz Moreno, Daniel Meraviglia-Crivelli, et al.
Oncoimmunology|September 18, 2018
Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumorsMario M Soldevilla, Helena Villanueva, Naiara Martinez-Velez, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 14, 2019
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor ImmunityMario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Pageof 2